John Chidsey
John Chidsey's purchase track record
John Chidsey has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/22/2026 | NCLH | $2.50M | +5.8% | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
HCA Q2 Earnings and Analyst Optimism Amid Valuation Concerns. HCA Healthcare reported strong Q2 earnings compared to other hospital chains, prompting TD Cowen to raise its price target to $460. While some analysts note the stock could trade at a discount following a 96% run, others argue its strong outpatient partnerships and financial health make it too healthy to downgrade. The company's solid performance continues to draw attention from major market lists and value stock screens.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Encompass Health Sets Q3 2026 Earnings Call Date. Encompass Health announced the date for its 2026 third-quarter earnings call. Recent coverage also highlights the company's small-format expansion strategy and potential undervaluation as it builds out its rehabilitation capacity. The stock is currently trading near the lower end of its 52-week range, with an average analyst target of $148.17.
Transaction History
| NCLH | ▲ Buy | Open Market | 153,000 | $2.5M | 5/22/2026 | View on chart |
| HCA | ▲ Buy | Grant | 809 | $0 | 4/28/2026 | View on chart |
| NCLH | ▲ Buy | Grant | 967,254 | $0 | 3/26/2026 | View on chart |
| NCLH | ▲ Buy | Grant | 13,169 | $0 | 1/2/2026 | View on chart |
| HCA | ▲ Buy | Grant | 496 | $0 | 7/29/2025 | View on chart |
| NCLH | ▲ Buy | Grant | 6,517 | $0 | 2/5/2025 | View on chart |
| EHC | ▲ Buy | Grant | 234 | $19K | 4/16/2024 | View on chart |
| EHC | ▲ Buy | Grant | 176 | $0 | 4/15/2024 | View on chart |
| EHC | ▲ Buy | Grant | 495 | $35K | 1/17/2024 | View on chart |
| EHC | ▲ Buy | Grant | 199 | $0 | 1/16/2024 | View on chart |
| EHC | ▲ Buy | Grant | 541 | $35K | 10/17/2023 | View on chart |
| EHC | ▲ Buy | Grant | 222 | $0 | 10/16/2023 | View on chart |
| EHC | ▲ Buy | Grant | 448 | $30K | 7/18/2023 | View on chart |
| EHC | ▲ Buy | Grant | 209 | $0 | 7/17/2023 | View on chart |
| EHC | ▲ Buy | Grant | 2,385 | $0 | 5/4/2023 | View on chart |
| EHC | ▲ Buy | Grant | 687 | $42K | 4/18/2023 | View on chart |
| EHC | ▲ Buy | Grant | 223 | $0 | 4/17/2023 | View on chart |
| EHC | ▲ Buy | Grant | 224 | $0 | 1/17/2023 | View on chart |
| EHC | ▲ Buy | Grant | 682 | $42K | 1/17/2023 | View on chart |
| EHC | ▲ Buy | Grant | 848 | $42K | 10/18/2022 | View on chart |
| EHC | ▲ Buy | Grant | 279 | $0 | 10/17/2022 | View on chart |
| EHC | ▲ Buy | Grant | 1,003 | $51K | 8/1/2022 | View on chart |
| EHC | ▲ Buy | Grant | 514 | $0 | 7/20/2022 | View on chart |
| EHC | ▲ Buy | Grant | 2,226 | $0 | 5/5/2022 | View on chart |
| EHC | ▲ Buy | Grant | 633 | $46K | 4/19/2022 | View on chart |
| EHC | ▲ Buy | Grant | 285 | $0 | 4/18/2022 | View on chart |
| EHC | ▲ Buy | Grant | 498 | $31K | 1/20/2022 | View on chart |
| EHC | ▲ Buy | Grant | 231 | $14K | 1/19/2022 | View on chart |
| EHC | ▲ Buy | Grant | 328 | $0 | 1/18/2022 | View on chart |
| EHC | ▲ Buy | Grant | 214 | $14K | 10/18/2021 | View on chart |
| EHC | ▲ Buy | Grant | 298 | $0 | 10/15/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
NCLH Debt Refinancing Boosts Booking Momentum
NCLH announced a new debt refinancing plan that could reduce its borrowing costs and has been cited as a reason for the stock being undervalued by up to 29%. The company also reported record bookings for the next fiscal year and is encouraging earlier reservations to ease yield pressure. These developments suggest the firm is improving its financial position and could be attractive to investors looking for value.
NCLH Debt Refinancing Boosts Booking Momentum. NCLH announced a new debt refinancing plan that could reduce its borrowing costs and has been cited as a reason for the stock being undervalued by up to 29%. The company also reported record bookings for the next fiscal year and is encouraging earlier reservations to ease yield pressure. These developments suggest the firm is improving its financial position and could be attractive to investors looking for value.